Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by Surgery
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Pfizer
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Merck Sharp & Dohme LLC
Polynoma LLC
Merck Sharp & Dohme LLC
Novartis
Incyte Corporation
University Hospital, Limoges
Hoffmann-La Roche
NRG Oncology
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Novartis
Bristol-Myers Squibb
Galderma R&D
Bristol-Myers Squibb
LEO Pharma
LEO Pharma
LEO Pharma
LEO Pharma
LEO Pharma
LEO Pharma
LEO Pharma
LEO Pharma
Bristol-Myers Squibb
LEO Pharma
Universitaire Ziekenhuizen KU Leuven
Merck Sharp & Dohme LLC
Eisai Inc.
Sol-Gel Technologies, Ltd.
Galderma R&D
Galderma R&D
Nova Scotia Health Authority
Sol-Gel Technologies, Ltd.
Kyowa Kirin Co., Ltd.
Almirall, S.A.
Galderma R&D
Novartis
Biofrontera Bioscience GmbH
Galderma R&D
Nektar Therapeutics
National Cancer Institute, Naples
Milton S. Hershey Medical Center